The primary objective of this study is to compare the efficacy of early (presumptive vs diagnostic driven) Primary Therapy of documented Invasive Aspergillosis (IA) in high-risk patients using Voriconazole containing regiment in comparison with amphotericin B based Therapy. This is a multicenter international study that aims at evaluating the global experience, Far East (Japan), Middle East (Lebanon) and South America (Brazil).
All patients diagnosed with probable or definite invasive aspergillosis admitted to AUBMC.
The patient population to be included will consist of high–risk patients with hematologic malignancy, HSCT and ICU critically ill patients with invasive aspergillosis.
1- Age range of patients: 12-86 years of age
2- Patients with a proven or probable invasive aspergillosis (e.g., patients who have had a CT scan of the chest done with either a documented positive culture for aspergillosis or a documented positive galactomannan test in Bal or blood whereby the appropriate antifungal therapy was started early (Empiric VS diagnostic driven)
1. Subjects with other fungal infection such as (mucormycosis, fusariosis, etc.)
2. Subjects with hematologic malignancy/ critically ill /HSCT who did not have a positive culture or biopsy positive for aspergillosis (Possible IA)